{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:16:53Z","timestamp":1791605813321,"version":"4.3.4"},"reference-count":120,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/14712598.2026.2664733","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:08:56Z","timestamp":1777403336000},"page":"487-501","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal antibodies in the management of hereditary angioedema"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-1721","authenticated-orcid":false,"given":"Henriette","family":"Farkas","sequence":"first","affiliation":[{"name":"Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2636-9740","authenticated-orcid":false,"given":"Lili","family":"Voloncs-Mindszenthy","sequence":"additional","affiliation":[{"name":"Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-420X","authenticated-orcid":false,"given":"Hanga R\u00e9ka","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Semmelweis University","place":["Budapest, Hungary"]},{"name":"Borsod-Abauj-Zemplen County Central Hospital and University Teaching Hospital","place":["Miskolc, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-025-00999-8"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2006.08.003"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8561-8"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2017.04.001"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-04-0250"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.05.017"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092023"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100223"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09027-4"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2019.40.4267"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03265-z"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0376-8"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188794"},{"issue":"49","key":"e_1_3_5_17_1","first-page":"2183","article-title":"On the development of immunity to diphtheria and tetanus in animals","volume":"90","author":"Behring K","year":"1965","unstructured":"Behring K. On the development of immunity to diphtheria and tetanus in animals. Dtsch Med Wochenschr. 1965;90(49):2183.","journal-title":"Dtsch Med Wochenschr"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01521a071"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj0730119"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651050-00010"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.70127"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)01034-5"},{"key":"e_1_3_5_24_1","unstructured":"Organization WH. New INN nomenclature scheme for monoclonal antibodies 2022. Available from: https:\/\/www.who.int\/publications\/m\/item\/inn-22-542"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0987-2"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02180-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.03.016"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.569061"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.05.028"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605767"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.16773"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16909"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.09.009"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-017-0172-9"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15011"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13180"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6162"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70099"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02225-X"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00081-4"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00350-1"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16351"},{"key":"e_1_3_5_43_1","unstructured":"Study of lanadelumab in healthy Japanese and matched caucasian adult subjects. 2021 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03401671"},{"key":"e_1_3_5_44_1","unstructured":"A study to determine the bioavailability of lanadelumab (SHP643) administered subcutaneously with the prefilled syringe and the autoinjector in healthy adult volunteer participants. 2020 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03918239"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14680"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14416"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13974"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.08.001"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00721-y"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12806"},{"key":"e_1_3_5_51_1","unstructured":"A study of lanadelumab (SHP643) in Chinese participants with hereditary angioedema (hae). 2024 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05460325"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03226-3"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-025-01007-9"},{"key":"e_1_3_5_54_1","unstructured":"A study of lanadelumab in persons with hereditary angioedema (hae) type I or ii (enable). 2025 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04130191"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70072"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.07.025"},{"issue":"3","key":"e_1_3_5_57_1","first-page":"73","article-title":"Effectiveness and safety of lanadelumab according to disease activity: pooled analysis of EMPOWER\/ENABLE","volume":"72","author":"Martinez-Saguer I","year":"2025","unstructured":"Martinez-Saguer I, Zanichelli A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. Effectiveness and safety of lanadelumab according to disease activity: pooled analysis of EMPOWER\/ENABLE. Rev Alerg Mex. 2025;72(3):73\u201374.","journal-title":"Rev Alerg Mex"},{"key":"e_1_3_5_58_1","unstructured":"A study of lanadelumab in teenagers and adults with hereditary angioedema (hae) in the Kingdom of Saudi Arabia. 2025 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07263685"},{"key":"e_1_3_5_59_1","unstructured":"A study with lanadelumab in persons with hereditary angioedema (hae) in Poland (CHOPIN). 2025 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05147181"},{"key":"e_1_3_5_60_1","unstructured":"A study of lanadelumab in teenagers and adults with hereditary angioedema (hae). 2025 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05469789"},{"key":"e_1_3_5_61_1","unstructured":"A study of lanadelumab in teenagers and adults with hereditary angioedema (hae) in Argentina. 2023 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04955964"},{"key":"e_1_3_5_62_1","unstructured":"A study of lanadelumab (Takhzyro) and icatibant (Firazyr\u00ae) in persons with hae in China 2026 Available from: https:\/\/clinicaltrials.gov\/study\/NCT06346899"},{"key":"e_1_3_5_63_1","unstructured":"A survey of lanadelumab in participants with hereditary angioedema. 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT05397431"},{"key":"e_1_3_5_64_1","unstructured":"A study of lanadelumab in children with hereditary angioedema (hae) in multiple countries. 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT07251933"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5269"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00664-4"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405317"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.04.072"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14785"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110542"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.0000000000000102"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1636425"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.1120"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15620"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2024.45.240046"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1159\/000546987"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-025-00505-x"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00470-x"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00579-6"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03988-7"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101165"},{"issue":"3","key":"e_1_3_5_82_1","first-page":"221","article-title":"Initial experience of long-term prophylaxis with lanadelumab for hereditary angioedema in China: a clinical observation study on six patients","volume":"186","author":"Yao W","year":"2025","unstructured":"Yao W, Diao R, Yang B, et al. Initial experience of long-term prophylaxis with lanadelumab for hereditary angioedema in China: a clinical observation study on six patients. Int Arch Allergy Immunol. 2025;186(3):221\u2013231.","journal-title":"Int Arch Allergy Immunol"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100664"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100166"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17106"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2025.01045"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100918"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.12.008"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61111897"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-263989"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1696666"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1554940"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.29262\/ram.v70i3.1270"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1472390"},{"issue":"9","key":"e_1_3_5_95_1","first-page":"390","article-title":"Successful use of lanadelumab in an older patient with type ii hereditary angioedema","volume":"39","author":"Hellu MT","year":"2022","unstructured":"Hellu MT, Weiss MS, Smith D. Successful use of lanadelumab in an older patient with type ii hereditary angioedema. Fed Pract. 2022;39(9):390\u2013392.","journal-title":"Fed Pract"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03251-5"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2025.04.059"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae501"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.29262\/ram.v71i4.1323"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.014"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006804"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13192"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14568"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2025.46.250026"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2025.46.250027"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70009"},{"key":"e_1_3_5_107_1","unstructured":"CSL312_3003 safety and pharmacokinetic study in subjects 2 to 11 years of age with hereditary angioedema. 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT05819775"},{"key":"e_1_3_5_108_1","unstructured":"A study investigating the Effectiveness and safety of garadacimab for treating patients with hereditary angioedema (HAE) (GREAT). 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT07001280"},{"key":"e_1_3_5_109_1","unstructured":"Safety study in subjects \u2265 12 years of age with hereditary angioedema switching to garadacimab 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT06806657"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001740"},{"key":"e_1_3_5_111_1","unstructured":"A study of STAR-0215 in participants with hereditary angioedema. 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT05695248"},{"key":"e_1_3_5_112_1","unstructured":"A long-term study of STAR-0215 in participants with hereditary angioedema. 2025 Available from: https:\/\/clinicaltrials.gov\/study\/NCT06007677"},{"key":"e_1_3_5_113_1","unstructured":"A study of navenibart in participants with hereditary angioedema (ALPHA-ORBIT). 2026 Available from: https:\/\/clinicaltrials.gov\/study\/NCT06842823"},{"key":"e_1_3_5_114_1","unstructured":"A long-term study of navenibart in participants with hereditary angioedema. 2025 [cited 2026 Jan 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07204938"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-025-00511-y"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0237"},{"key":"e_1_3_5_117_1","volume-title":"Pharmacoeconomic review report: lanadelumab (Takhzyro): (shire Pharma Canada ULC): indication: for the routine prevention of attacks of hereditary angioedema in adolescents and adults","author":"CADTH Common Drug Reviews","year":"2020","unstructured":"CADTH Common Drug Reviews. Pharmacoeconomic review report: lanadelumab (Takhzyro): (shire Pharma Canada ULC): indication: for the routine prevention of attacks of hereditary angioedema in adolescents and adults. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2020 Canadian Agency for Drugs and Technologies in Health.; 2020."},{"key":"e_1_3_5_118_1","volume-title":"Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over","author":"National Institute for Health and Care Excellence: Technology Appraisals","year":"2025","unstructured":"National Institute for Health and Care Excellence: Technology Appraisals. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over. London: National Institute for Health and Care Excellence (NICE) \u00a9 nice; 2025."},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03562-1"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-09006-1"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.043"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70207"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2664733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:37:52Z","timestamp":1779950272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2664733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/14712598.2026.2664733"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2664733","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}